HSPB1 and brain ischemia: Intravenous infusion of human-derived HSPB1 or recombinant HSPB1 with a cell-penetrating peptide reduced blood-brain barrier dysfunction and improved neurological deficits, including reduced glia activation in mice following brain ischemia (90,91).